Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexibly Dosed Paliperidone ER in Schizophrenia
NCT01662648Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of paliperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 26 weeks. Started Jun 2007; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01662648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662648.